603127.SH
JOINN Laboratories (China) Co., Ltd.
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 46.31
+6.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9B | 1.7B | 2.0B | 2.4B | 2.3B |
| Cost of Revenue | 1.4B | 1.3B | 1.4B | 1.4B | 1.2B |
| Gross Profit | 447.6M | 343.3M | 573.8M | 1.0B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 88.4M | 87.4M | 92.9M | 96.9M | 78.0M |
| SG&A Expense | 66.0M | — | — | — | — |
| General & Admin Expense | 119.1M | 282.3M | 289.2M | 280.3M | 286.6M |
| Selling & Marketing Expense | 21.7M | 36.9M | 27.9M | 24.6M | 18.0M |
| Other Expenses | 106.2M | — | — | — | — |
| Total Operating Expenses | 396.6M | 348.9M | 319.2M | 258.3M | 237.1M |
| Cost and Expenses | 1.8B | 1.7B | 1.8B | 1.6B | 1.4B |
| Operating Income (EBIT) | 528.7M | 338.0M | 104.3M | 507.1M | 1.2B |
| Non-Operating | |||||
| Interest Income | 40.3M | — | — | — | — |
| Interest Expense | 567.2K | — | — | — | — |
| Net Interest Income | 39.7M | — | — | — | — |
| Other Non-Op Income/Expense | 725.4M | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.3B | 337.5M | 104.0M | 507.0M | 1.2B |
| Income Tax Expense | 109.0M | 39.7M | 34.3M | 115.4M | 166.8M |
| Bottom Line | |||||
| Net Income | 1.1B | 297.8M | 74.1M | 397.0M | 1.1B |
| Earnings from Cont. Ops | 1.1B | 297.8M | 69.8M | 391.6M | 1.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.1B | 297.8M | 74.1M | 397.0M | 1.1B |
| Per Share | |||||
| Basic EPS | CN¥1.55 | CN¥0.40 | CN¥0.10 | CN¥0.53 | CN¥1.44 |
| Diluted EPS | CN¥1.55 | CN¥0.40 | CN¥0.10 | CN¥0.53 | CN¥1.43 |
| Revenue Per Share | CN¥2.53 | CN¥2.23 | CN¥2.72 | CN¥3.17 | CN¥3.04 |
| Shares | |||||
| Basic Shares Outstanding | 733.4M | 744.6M | 740.8M | 749.0M | 746.0M |
| Diluted Shares Outstanding | 733.4M | 744.6M | 740.8M | 749.0M | 746.0M |
| Profitability Metrics | |||||
| EBITDA | 72.0M | 469.6M | 223.9M | 626.1M | 1.3B |
| D&A | 37.7M | 131.6M | 119.5M | 119.0M | 107.0M |
| EBIT | 34.3M | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026